Alnylam Pharmaceuticals, Inc. (ALNY)

NASDAQ: ALNY · Real-Time Price · USD

401.80

+9.56 (2.44%)

At close: Aug 1, 2025, 4:00 PM

399.55

-2.25 (-0.56%)

After-hours: Aug 1, 2025, 5:59 PM EDT

CTI BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2020
Revenue	2,462	2,248	1,828	1,037	844.29	492.85	Upgrade
Revenue Growth (YoY)	5.01%	22.97%	76.23%	22.88%	71.31%	124.28%	Upgrade
Cost of Revenue	413.7	323.37	310.41	168.82	140.14	78.05	Upgrade
Gross Profit	2,048	1,925	1,518	868.6	704.14	414.8	Upgrade
Selling, General & Admin	1,080	975.53	795.65	770.66	620.64	588.42	Upgrade
Research & Development	1,149	1,126	1,004	883.02	792.16	654.82	Upgrade
Operating Expenses	2,228	2,102	1,800	1,654	1,413	1,243	Upgrade
Operating Income	-180.19	-176.89	-282.18	-785.07	-708.65	-828.44	Upgrade
Interest Expense	-152.24	-141.86	-121.22	-155.97	-143.02	-84.5	Upgrade
Interest & Investment Income	119.32	121.99	95.56	24.81	1.58	11.81	Upgrade
Other Non Operating Income (Expenses)	-163.45	-177.6	-108.74	-100.86	-57.75	-8.52	Upgrade
EBT Excluding Unusual Items	-376.55	-374.35	-416.57	-1,017	-907.84	-909.64	Upgrade
Gain (Loss) on Sale of Investments	-3.02	-3.02	-16.94	-33.31	55.7	54.04	Upgrade
Other Unusual Items	-	-	-	-76.59	-	-	Upgrade
Pretax Income	-379.58	-377.38	-433.52	-1,127	-852.14	-855.6	Upgrade
Income Tax Expense	-60.49	-99.22	6.73	4.16	0.68	2.68	Upgrade
Net Income	-319.09	-278.16	-440.24	-1,131	-852.82	-858.28	Upgrade
Net Income to Common	-319.09	-278.16	-440.24	-1,131	-852.82	-858.28	Upgrade
Shares Outstanding (Basic)	130	128	125	122	118	115	Upgrade
Shares Outstanding (Diluted)	130	128	125	122	118	115	Upgrade
Shares Change (YoY)	2.84%	2.20%	2.64%	2.73%	3.01%	5.24%	Upgrade
EPS (Basic)	-2.46	-2.18	-3.52	-9.30	-7.20	-7.46	Upgrade
EPS (Diluted)	-2.46	-2.18	-3.52	-9.30	-7.20	-7.46	Upgrade
Free Cash Flow	-	-42.59	41.95	-613.33	-718.07	-685.32	Upgrade
Free Cash Flow Per Share	-	-0.33	0.34	-5.04	-6.06	-5.96	Upgrade
Gross Margin	83.20%	85.62%	83.02%	83.73%	83.40%	84.16%	Upgrade
Operating Margin	-7.32%	-7.87%	-15.43%	-75.68%	-83.94%	-168.09%	Upgrade
Profit Margin	-12.96%	-12.37%	-24.08%	-109.04%	-101.01%	-174.14%	Upgrade
Free Cash Flow Margin	-	-1.89%	2.29%	-59.12%	-85.05%	-139.05%	Upgrade
EBITDA	-123.23	-120.22	-228.12	-740.6	-661.09	-793.67	Upgrade
EBITDA Margin	-5.00%	-5.35%	-12.48%	-71.39%	-78.30%	-161.03%	Upgrade
D&A For EBITDA	56.96	56.67	54.05	44.47	47.57	34.77	Upgrade
EBIT	-180.19	-176.89	-282.18	-785.07	-708.65	-828.44	Upgrade
EBIT Margin	-7.32%	-7.87%	-15.43%	-75.67%	-83.94%	-168.09%	Upgrade
Revenue as Reported	2,462	2,248	1,828	1,037	844.29	492.85	Upgrade
Advertising Expenses	-	29.7	12.4	11.7	-	-	Upgrade

Updated Jul 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q